Danaher (DHR) on Tuesday reported better-than-expected fiscal first-quarter results, while the medical technology company said it expects adjusted core revenue growth on a sequential basis in the ongoing quarter.

Non-GAAP core revenue is set to rise by low single-digits year over year for the three-month period ending June 27, according to the company. The metric remained flat in the prior quarter, exceeding the firm's expectations for a low-single-digit decrease, while the current consensus on FactSet is for sales of $5.74 billion for the second quarter.

The medical equipment maker expects core revenue in its biotechnology segment to increase by 7% in the second quarter, while the diagnostics business is pegged to rise by low single digits. It anticipates core revenue in the life sciences division to decline by low- to mid-single-digits.

"We expect end market demand remains relatively consistent with the first quarter for the remainder of 2025," Chief Executive Rainer Blair said during an earnings call, according to a FactSet transcript. The stock was up 5.7% in Tuesday trade.

Danaher reiterated its full-year adjusted core revenue growth outlook of about 3%. The company also issued guidance for adjusted earnings to be in a range of $7.60 to $7.75 per share for fiscal 2025. "Given the current environment, we believe providing adjusted EPs guidance offers the best anchor point for assessing business performance and will provide better clarity for our investors," Blair said on the call.

The Street is looking for non-GAAP EPS of $7.66 and sales of $24.15 billion for the ongoing year.

The company believes it can "largely offset" tariff-related headwinds through a "combination of supply chain adjustments, surcharges, manufacturing footprint changes and other cost actions," Blair told analysts on the call.

After announcing sweeping new tariffs on US imports earlier this month, President Donald Trump declared a 90-day pause on certain tariffs for non-retaliating countries. China responded with its own retaliatory duties, and Washington and Beijing have since raised tariffs on each other's goods multiple times.

For the quarter ended March 28, Danaher posted adjusted EPS of $1.88 versus $1.92 the year before, surpassing the average analyst estimate of $1.63. Sales ticked down 1% to $5.74 billion, ahead of the market view of $5.57 billion.

"Revenue, earnings, and cash flow exceeded our expectations in the first quarter-highlighted by continued momentum in bioprocessing and better-than-expected respiratory demand in our molecular diagnostics business," Blair said in the earnings release.

Sales in the life sciences division decreased to $1.68 billion from $1.75 billion in the 2024 quarter, while biotechnology rose to $1.61 billion from $1.52 billion, according to an earnings presentation. Diagnostics revenue fell to $2.45 billion from $2.53 billion last year.